Streetbeat News

FWBI

First Wave BioPharma Inc

https://www.azurrx.com/

CEO

James Sapirstein

Employees

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.

Open

2.93

Mkt cap

Volume

56K

High

3.04

P/E Ratio

-0.06

52-wk high

60.00

Low

2.84

Div yield

N/A

52-wk low

2.33

First Wave BioPharma has announced the publication of two patent applications for the composition of matter and methods of use claims governing its enhanced enteric microgranule delivery formulation of Adrulipase.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 11:11 am

First Wave BioPharma Inc has filed for a shelf offering of up to 3.4 million shares of common stock by selling stockholders, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2023 | 8:30 pm

First Wave Bio has received a Notice of Allowance for its U.S. patent application 17/163,996, titled 'Methods and Compositions for Treating Conditions Associated with an Abnormal Inflammatory Response'.

Portfolio Pulse from Benzinga Newsdesk

June 15, 2023 | 4:18 pm

US stocks traded higher with Nasdaq Composite gaining over 50 points. IperionX Limited (IPX) shares rose 116% after agreeing to supply titanium components for Ford Motor Company. First Wave BioPharma (FWBI) shares spiked 78% after achieving its enrollment target for its Phase 2 SPAN trial.

Portfolio Pulse from Lisa Levin

June 13, 2023 | 6:44 pm

During Tuesday's intraday session, several health care stocks experienced significant price movements. Gainers included FWBI, HOOK, GRCL, ABOS, DERM, and AKYA, while losers were ZJYL, CBUS, BIOR, MOTS, AXDX, and TNON.

Portfolio Pulse from Benzinga Insights

June 13, 2023 | 5:33 pm

First Wave BioPharma (NASDAQ: FWBI) has entered into agreements to exercise existing warrants for 1,681,667 shares at a reduced price of $1.15 per share, in exchange for new warrants. The transaction is expected to generate $2.4 million in gross proceeds.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 4:52 pm

Motorcar Parts of America shares rose 13.5% after reporting Q4 profit. Other stocks with significant gains include First Wave BioPharma, IperionX, Ideanomics, and Cepton. Losers include Auddia, Advanced Health Intelligence, Bonso Electronics, and Jin Medical International.

Portfolio Pulse from Lisa Levin

June 13, 2023 | 4:47 pm

Crude oil prices rose sharply, and U.S. stocks traded higher with Dow Jones gaining over 100 points. IperionX Limited (IPX) shares surged after agreeing to supply titanium metal components for Ford Motor Company. Auddia Inc. (AUUD) shares plummeted after pricing a $3.1 million registered direct offering of common stock.

Portfolio Pulse from Lisa Levin

June 13, 2023 | 4:02 pm

In the last 3 months, 4 analysts have offered 12-month price targets for First Wave BioPharma (NASDAQ:FWBI), with an average price target of $12.0, a 25.0% decrease from the previous average price target of $16.00.

Portfolio Pulse from Benzinga Insights

June 13, 2023 | 4:00 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on First Wave BioPharma (NASDAQ:FWBI) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

June 13, 2023 | 3:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.